Previous 10 | Next 10 |
After the Food and Drug Administration paused Allogene Therapeutics ' (NASDAQ: ALLO) clinical trials last week, the stock was crushed. It has rebounded 31% this week through Thursday, according to data from S&P Global Market Intelligence . That still leaves it down 30% s...
Palm Beach, FL – October 14, 2021 – FinancialNewsMedia.com News Commentary – The breast cancer drugs market, which has been steadily growing over the past few years, is projected to continue this trend for the next several years. The breast cancer drugs mark...
Gainers: Hyzon Motors HYZN +5%. Avadel Pharmaceuticals (NASDAQ:AVDL) +4%. Allogene Therapeutics (NASDAQ:ALLO) +4%. Latch (NASDAQ:LTCH) +2%. Old National Bancorp (NASDAQ:ONB) +2%. Losers: Xiaobai Maimai (NASDAQ:HX) -4%. Clarus Therapeutics Holdings (NASDAQ:CRXT) -4%. Relay Thera...
Adding to post-market losses on Tuesday, CRISPR Therapeutics (NASDAQ:CRSP) has slipped another ~8.2% in early hours after the company’s gene-edited allogeneic CAR-T cell therapy CTX110 failed to excite investors with data from an early-stage trial in CD19+ B-cell maligna...
The situation around the clinical hold is unclear and will take at least a few months to resolve. The risk-reward opportunity is very high. I am taking a risk and buying. For further details see: Allogene Therapeutics: I Am Buying On The Clinical Hold Dip
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks and U.S. Treasurys fell Friday after a weak jobs report added to speculation about the Federal Reserve's plan to taper its bond-buying...
While stocks finished fractionally lower on Friday after a disappointing payroll report, oil prices continued their steady climb, driving to a multi-year high. This powered stocks in the sector, with APA Corp. (NASDAQ:APA), Pioneer Natural Resources (NYSE:PXD), Hess Corp. (NYSE:HES) and EOG R...
Shares of Allogene Therapeutics Inc ( NASDAQ: ALLO ) tanked 45% to $13.35 on Friday after the U.S. FDA put a hold on its Cancer drug trial. The sharp decline wiped millions off Allogene’s market cap, leaving the California-based firm with a valuation of $1.90 billion. ...
The stock market posted mixed results on Friday morning, as investors continued to wrestle with countervailing factors in making their investment decisions. As of 11:45 a.m. EDT, the Nasdaq Composite (NASDAQINDEX: ^IXIC) was trailing other major benchmarks, falling about a quarter p...
Shares of the off-the-shelf cell therapy company Allogene Therapeutics (NASDAQ: ALLO) are ending the week on a sour note. The biotech's stock is down by a jaw-dropping 44% as of 11:36 a.m. EDT Friday morning. Allogene's shares are plunging today after the U.S. Food and Drug Admi...
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
NASDAQ Market:
Allogene Therapeutics Inc. Website:
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC) ALLO-316 Illustrates Proof-of-Concept in RCC and the Potential of Dagger ® Technology to Optimize CAR T Cell Expansion and Pe...
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology compan...